218 related articles for article (PubMed ID: 32695752)
1. Immune and Clinical Features of
Zhang Q; Zhong H; Fan Y; Liu Q; Song J; Yao S; Cao F
Front Bioeng Biotechnol; 2020; 8():592. PubMed ID: 32695752
[TBL] [Abstract][Full Text] [Related]
2. CD96, a new immune checkpoint, correlates with immune profile and clinical outcome of glioma.
Liu F; Huang J; He F; Ma X; Fan F; Meng M; Zhuo Y; Zhang L
Sci Rep; 2020 Jul; 10(1):10768. PubMed ID: 32612110
[TBL] [Abstract][Full Text] [Related]
3. Large-scale analysis reveals the specific clinical and immune features of B7-H3 in glioma.
Zhang C; Zhang Z; Li F; Shen Z; Qiao Y; Li L; Liu S; Song M; Zhao X; Ren F; He Q; Yang B; Fan R; Zhang Y
Oncoimmunology; 2018; 7(11):e1461304. PubMed ID: 30377558
[No Abstract] [Full Text] [Related]
4. Interferon gamma-related gene signature based on anti-tumor immunity predicts glioma patient prognosis.
Zhang Z; Shen X; Tan Z; Mei Y; Lu T; Ji Y; Cheng S; Xu Y; Wang Z; Liu X; He W; Chen Z; Chen S; Lv Q
Front Genet; 2022; 13():1053263. PubMed ID: 36712869
[No Abstract] [Full Text] [Related]
5. Molecular and clinical characterization of CD163 expression via large-scale analysis in glioma.
Liu S; Zhang C; Maimela NR; Yang L; Zhang Z; Ping Y; Huang L; Zhang Y
Oncoimmunology; 2019; 8(7):1601478. PubMed ID: 31143523
[TBL] [Abstract][Full Text] [Related]
6. CD96 Correlates With Immune Infiltration and Impacts Patient Prognosis: A Pan-Cancer Analysis.
Ye W; Luo C; Liu F; Liu Z; Chen F
Front Oncol; 2021; 11():634617. PubMed ID: 33680972
[TBL] [Abstract][Full Text] [Related]
7. Molecular and clinical characterization of TIM-3 in glioma through 1,024 samples.
Li G; Wang Z; Zhang C; Liu X; Cai J; Wang Z; Hu H; Wu F; Bao Z; Liu Y; Zhao L; Liang T; Yang F; Huang R; Zhang W; Jiang T
Oncoimmunology; 2017; 6(8):e1328339. PubMed ID: 28919992
[No Abstract] [Full Text] [Related]
8. Comprehensive Analysis of PD-1 Gene Expression, Immune Characteristics and Prognostic Significance in 1396 Glioma Patients.
Liu C; Zhang Z; Ping Y; Qin G; Zhang K; Maimela NR; Huang L; Yang S; Zhang Y
Cancer Manag Res; 2020; 12():4399-4410. PubMed ID: 32606935
[TBL] [Abstract][Full Text] [Related]
9. Characterization of transcriptome profile and clinical features of a novel immunotherapy target CD204 in diffuse glioma.
Yuan Y; Zhao Q; Zhao S; Zhang P; Zhao H; Li Z; Du Y; Tian X; Lu J
Cancer Med; 2019 Jul; 8(8):3811-3821. PubMed ID: 31140757
[TBL] [Abstract][Full Text] [Related]
10. MELK is a prognostic biomarker and correlated with immune infiltration in glioma.
Yang H; Zhou H; Wang G; Tian L; Li H; Zhang Y; Xue X
Front Neurol; 2022; 13():977180. PubMed ID: 36353126
[TBL] [Abstract][Full Text] [Related]
11. CTLA-4 correlates with immune and clinical characteristics of glioma.
Liu F; Huang J; Liu X; Cheng Q; Luo C; Liu Z
Cancer Cell Int; 2020; 20():7. PubMed ID: 31911758
[TBL] [Abstract][Full Text] [Related]
12. Molecular and clinical characterization of PD-L1 expression at transcriptional level via 976 samples of brain glioma.
Wang Z; Zhang C; Liu X; Wang Z; Sun L; Li G; Liang J; Hu H; Liu Y; Zhang W; Jiang T
Oncoimmunology; 2016; 5(11):e1196310. PubMed ID: 27999734
[No Abstract] [Full Text] [Related]
13. Molecular and clinical characterization of PTPN2 expression from RNA-seq data of 996 brain gliomas.
Wang PF; Cai HQ; Zhang CB; Li YM; Liu X; Wan JH; Jiang T; Li SW; Yan CX
J Neuroinflammation; 2018 May; 15(1):145. PubMed ID: 29764444
[TBL] [Abstract][Full Text] [Related]
14. Molecular and Clinical Characterization of a Novel Prognostic and Immunologic Biomarker FAM111A in Diffuse Lower-Grade Glioma.
Ji X; Ding F; Gao J; Huang X; Liu W; Wang Y; Liu Q; Xin T
Front Oncol; 2020; 10():573800. PubMed ID: 33194678
[TBL] [Abstract][Full Text] [Related]
15. Impact of intratumoural CD96 expression on clinical outcome and therapeutic benefit in gastric cancer.
Xu C; Fang H; Gu Y; Yu K; Wang J; Lin C; Zhang H; Li H; He H; Liu H; Li R
Cancer Sci; 2022 Dec; 113(12):4070-4081. PubMed ID: 35997524
[TBL] [Abstract][Full Text] [Related]
16. Three Immune-Associated Subtypes of Diffuse Glioma Differ in Immune Infiltration, Immune Checkpoint Molecules, and Prognosis.
Zhou Q; Yan X; Liu W; Yin W; Xu H; Cheng D; Jiang X; Ren C
Front Oncol; 2020; 10():586019. PubMed ID: 33425739
[TBL] [Abstract][Full Text] [Related]
17. Large-Scale Analysis Reveals the Specific Clinical and Immune Features of DGCR5 in Glioma.
Wu X; Hou P; Qiu Y; Wang Q; Lu X
Onco Targets Ther; 2020; 13():7531-7543. PubMed ID: 32801772
[TBL] [Abstract][Full Text] [Related]
18. Specific clinical and immune features of CD68 in glioma via 1,024 samples.
Wang L; Zhang C; Zhang Z; Han B; Shen Z; Li L; Liu S; Zhao X; Ye F; Zhang Y
Cancer Manag Res; 2018; 10():6409-6419. PubMed ID: 30568502
[TBL] [Abstract][Full Text] [Related]
19. CDC42-A promising immune-related target in glioma.
Jiang T; Wang X; Huang J; Chen D
Front Neurosci; 2023; 17():1192766. PubMed ID: 37476838
[TBL] [Abstract][Full Text] [Related]
20. Molecular and Clinical Characterization of LIGHT/TNFSF14 Expression at Transcriptional Level
Yang Y; Lv W; Xu S; Shi F; Shan A; Wang J
Front Mol Biosci; 2021; 8():567327. PubMed ID: 34513918
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
